Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States
Authors:
- Nina P. RahimiNRNina P. Rahimi
- Paul W. ReadPRPaul W. Read
Open Access
Abstract
BACKGROUND: Patients with human papillomavirus (HPV)‐positive oropharyngeal carcinoma (OC) have better prognosis than patients with HPV‐negative OC. The objective of the current study was to assess how different practices across the United States treat patients with OC with respect to screening for HPV DNA or p16.METHODS: Five hundred forty‐two randomly selected radiation oncologists were sent an 11‐question survey by email regarding the use of HPV/p16 screening in OC. The questionnaire addressed demographics of the practice, intensity‐modulated radiotherapy (IMRT) use, screening practices for HPV DNA or p16, which year this began, the use of HPV or p16 data to direct patient care, and future plans for its use if it had not already been instituted.RESULTS: One hundred ninety‐two responses (39.6%) were received. Thirty‐five percent of respondents (67 of 188) reported screening for HPV DNA routinely, whereas 4.8% of respondents (9 of 188) reported screening for p16. Of the physicians who did not use screening techniques, 37.2% (44 of 118 respondents) reported future plans to institute these screening techniques, 20% (9 of 45 respondents) stated plans to institute these techniques in the next 6 months, 55.5% (25 of 45 respondents) stated plans to institute these techniques within 6 months to 1 year, and 22.2% (10 of 45 respondents) stated plans to institute these techniques within 1 to 2 years. Academic physicians were more likely to use screening techniques (62.7%; P < .001) compared with private practitioners (31.4%). Only 12.4% of respondents reported using HPV or p16 data to direct care.CONCLUSIONS: Approximately 40.4% of radiation oncology practices that responded to a survey in the United States screened for HPV DNA or p16 in OC, whereas only 12.4% used it to further direct care. This number appears to be growing rapidly. Clinical trials to further elucidate how HPV or p16 status should direct care in OC are warranted. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United StatesJournal of Clinical Oncology, 2008
- Clinical Implications of Human Papillomavirus in Head and Neck CancersJournal of Clinical Oncology, 2006
- Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable PrognosisJournal of Clinical Oncology, 2006
- Intensity‐modulated radiation therapy use in the U.S., 2004Cancer, 2005
- Correlation of Her-2/neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast CarcinomaThe Breast Journal, 2005
- Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survivalCancer, 2005
- Expression of p16 Protein Is Associated with Human Papillomavirus Status in Tonsillar Carcinomas and Has Implications on Survival2004
- A survey of intensity‐modulated radiation therapy use in the United StatesCancer, 2003
- Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil.Journal of Clinical Pathology, 1990